Tuberculosis Clinical Trial
Official title:
A Clinical Challenge Study to Evaluate Controlled Human Infection With BCG Administered by the Aerosol Inhaled Route in Historically BCG-vaccinated Healthy Adult Volunteers
Verified date | June 2022 |
Source | University of Oxford |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to evaluate the human clinical response to BCG challenge in historically BCG-vaccinated healthy adult volunteers. It will involve 12 participants in a controlled dose escalation. Bronchoscopies will be performed 14 days post-challenge to measure BCG recovered from bronchial samples. Blood tests will be taken to look at potential immunological markers of immunity.
Status | Active, not recruiting |
Enrollment | 12 |
Est. completion date | September 2023 |
Est. primary completion date | September 2023 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 50 Years |
Eligibility | Inclusion Criteria: - Healthy adults aged 18-50 years - Previously vaccinated with the BCG (at least 6 months prior to enrolment, as evidenced by a visible scar or documentation in medical or occupational health records) - Resident in or near Oxford for the duration of the study period - Provide written informed consent - Willing to allow the investigators to discuss the volunteer's medical history with their General Practitioner (or review summary care record, if available) - Allow the investigator to register volunteer details with a confidential database (The Over-volunteering Protection Service) to prevent concurrent entry into clinical studies/trials - Agreement to refrain from blood donation during the course of the study - For women of child-bearing potential only, willingness to practice continuous effective contraception (see below) during the study and a negative pregnancy test on the day(s) of screening, challenge and bronchoscopy - Able and willing (in the investigator's opinion) to comply with all study requirements - No clinically relevant findings in medical history or on physical examination - Screening IGRA negative - Willing to be tested for evidence of SARS-CoV-2 infection and to allow public health notification of the results Exclusion Criteria: - Any clinically significant respiratory disease, including asthma - Current smoker (defined as any smoking including e-cigarettes in the last 3 months) - History of anaphylaxis to vaccination or any allergy likely to be exacerbated by any component of the study agent, any essential study procedure, sedative drugs, or any local or general anaesthetic agents - Clinically significant history of skin disorder, allergy, atopy, cancer (except BCC of the skin or CIS of the cervix), cardiovascular disease, gastrointestinal disease, liver disease, renal disease, endocrine disorder, neurological illness, psychiatric disorder, drug or alcohol abuse - Any autoimmune conditions or immunodeficiency (including HIV) - Previous diagnosis or treatment for TB disease or latent TB infections - Clinical, radiological, or laboratory evidence of current active TB disease or latent TB infection - Previous receipt of any investigational TB vaccine - Positive HBsAg, HCV or HIV antibodies - Concurrent use of oral, inhaled or systemic steroid medication or use for more than 14 days within the last 6 months (steroids used as a cream or ointment are permissible), or the use of other immunosuppressive agents concurrently or for more than 14 days within the last 6 months - Administration of immunoglobulins and/or any blood products within the three months preceding the planned study challenge date - Current use of any medication or other drug taken through the nasal or inhaled route including cocaine or other recreational drugs - Any nasal, pharyngeal, or laryngeal finding which precludes bronchoscopy - Pregnancy, lactation or intention to become pregnant during study period - Previously resident for more than 12 months concurrently in a tropical climate where significant non-tuberculous mycobacterial exposure is likely - Shares a household with someone with clinically significant immunodeficiency (either from infection or medication) who is deemed to be at risk of developing disseminated BCG infection if exposed to BCG - Participation in another research study involving receipt of an investigational product in the 30 days preceding enrolment, or planned use during the study period - Clinically significant abnormality on screening chest radiograph - Clinically significant abnormality of lung function testing - Any clinically significant abnormality of screening blood or urine tests - Laboratory confirmed (PCR or antibody) SARS-Cov-2 infection, evidence of viral pneumonitis on chest radiograph or a high clinical suspicion of COVID-19 disease in the 3 months preceding enrolment. - A body mass index (BMI) of <18.5 or >45 - Any other significant disease, disorder, or finding, which, in the opinion of the investigator, may either put the volunteer at risk, affect the volunteer's ability to participate in the study or impair interpretation of the study data |
Country | Name | City | State |
---|---|---|---|
United Kingdom | Centre for Clinical Vaccinology and Tropical Medicine | Oxford | Oxfordshire |
Lead Sponsor | Collaborator |
---|---|
University of Oxford |
United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Identify laboratory markers of immune response that correlate with the levels of BCG recovered from bronchial and other samples. | Laboratory markers of innate and adaptive immunity, determined by ex-vivo ELISpot | Up to day 168 | |
Other | Identify laboratory markers of immune response that correlate with the levels of BCG recovered from bronchial samples. | Laboratory markers of innate and adaptive immunity, determined by ELISA | Up to day 168 | |
Other | Identify laboratory markers of immune response that correlate with the levels of BCG recovered from bronchial samples. | Laboratory markers of innate and adaptive immunity, determined by RNA sequence analysis | Up to day 168 | |
Other | Identify laboratory markers of immune response that correlate with the levels of BCG recovered from bronchial samples. | Laboratory markers of innate and adaptive immunity, determined by intracellular cytokine staining of blood and bronchial samples | Up to day 168 | |
Other | Identify laboratory markers of immune response that correlate with the levels of BCG recovered from bronchial samples. | Laboratory markers of innate and adaptive immunity, determined by BCG cfu counts and or molecular diagnostics on induced sputum | Up to day 168 | |
Other | Identify laboratory markers of immune response that correlate with the levels of BCG recovered from bronchial samples. | Laboratory markers of innate and adaptive immunity, determined by matrix from adapted mask collection | Up to day 168 | |
Primary | To quantify BCG recoverable from bronchial sample | Quantification of BCG culture by mycobacterial growth indicator tube (PCR quantification and DNA strip assay speciation as required) | Day 14 | |
Secondary | Adverse Events | Evaluation of the human clinical response to BCG challenge via collection of data on adverse events at each visit, via diary cards and lung function test results. | Up to day 168 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05738681 -
Efficacy of N-acetylcysteine to Prevent Anti-tuberculosis Drug-induced Liver Injury: A Randomized Controlled Trial
|
Phase 2/Phase 3 | |
Recruiting |
NCT05526885 -
Tuberculosis Diagnostic Trial of CAD4TB Screening Alone Compared to CAD4TB Screening Combined With a CRP Triage Test, Both Followed by Confirmatory Xpert MTB/RIF Ultra in Communities of Lesotho and South Africa
|
N/A | |
Completed |
NCT04369326 -
Community Initiated Preventive Therapy for TB
|
N/A | |
Recruiting |
NCT04568967 -
TB-CAPT EXULTANT - HIV
|
N/A | |
Completed |
NCT02337270 -
Phase 1 Clinical Trial of the Safety and Immunogenicity of an Adenovirus-based TB Vaccine Administered by Aerosol
|
Phase 1 | |
Not yet recruiting |
NCT06253715 -
Shortened Regimen for Drug-susceptible TB in Children
|
Phase 3 | |
Recruiting |
NCT04271397 -
Immunological Biomarkers in Tuberculosis Management
|
N/A | |
Withdrawn |
NCT03639038 -
Tuberculosis Diagnosis by Flow Cytometry
|
||
Completed |
NCT03199313 -
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Sutezolid
|
Phase 1 | |
Recruiting |
NCT04975178 -
Efficacy, Safety and Immunogenicity Evaluation of MTBVAC in Newborns in Sub-Saharan Africa
|
Phase 3 | |
Completed |
NCT04463680 -
Rifampin and the Contraceptive Implant
|
Phase 4 | |
Completed |
NCT03973970 -
Assessing the Ability of the T-SPOT®.TB Test (IQ)
|
||
Recruiting |
NCT04230395 -
Alcohol Reduction Among People With TB and HIV in India
|
N/A | |
Completed |
NCT04874948 -
Absorption, Elimination and Safety of 14C-labeled Radioactive BTZ-043, a New Compound in TB Treatment
|
Phase 1 | |
Active, not recruiting |
NCT02906007 -
Evaluating the Pharmacokinetics, Safety, and Tolerability of Bedaquiline in Infants, Children, and Adolescents With Multidrug-Resistant Tuberculosis, Living With or Without HIV
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT05917210 -
Peer-led Implementation of TB-HIV Education and Adherence Counseling in Uganda
|
N/A | |
Not yet recruiting |
NCT06017843 -
Impact Evaluation of Use of MATCH AI Predictive Modelling for Identification of Hotspots for TB Active Case Finding
|
N/A | |
Not yet recruiting |
NCT05845112 -
Start Taking Action For TB Diagnosis
|
||
Active, not recruiting |
NCT02715271 -
Study of TB Lesions Obtained in Therapeutical Surgery
|
||
Completed |
NCT02781909 -
Potential Efficacy and Safety of Using Adjunctive Ibuprofen for XDR-TB Tuberculosis
|
Phase 2 |